Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Chemists Make Strides to Simplify Drug Design, Synthesis

By Rice University | September 14, 2016

A one-step solution to make nitrogen-laden molecular precursors for the preparation of drugs and other bioactive molecules has been discovered by researchers at Rice University, the University of Texas Southwestern Medical Center (UTSWMC) and Brigham Young University.

Research announced this month in Sciencewill simplify the process and cut the cost of creating key nitrogen-containing functional groups for pharmaceuticals, said László Kürti, a synthetic chemist at Rice who developed the technique with his colleague at UTSWMC, John Falck.

It should also simplify the design of agrochemicals, functional materials and bioactive natural products, the researchers reported.

The technique involves making free amines, compounds with one or more nitrogen atoms that are essential to metabolic processes. Aromatic amines, which incorporate stable molecular fragments called aromatic rings, are substructures in more than a third of drug candidates, Kürti said.

“Nitrogen atoms give polarity to the molecules,” Kürti said. “They also help bind to molecules like proteins and enzymes. That’s why you see an abundance of nitrogen atoms in biologically active compounds, especially in active pharmaceutical ingredients that are used in medicines; they need to interact with biological systems.”

The team’s success achieves a previously elusive goal synthetic chemists have pursued for many years, Kürti said.

“There is huge demand for making these aromatic amines quickly and efficiently, and for decades now, people have been trying to make them with catalysts that contain transition metals (often used to speed up chemical reactions),” he said. “But the free aromatic amine products readily bind to these metal catalysts and can essentially poison the process.” A long-term goal of Kürti’s lab is to design simplified amination chemistry that avoids the use of transition metals.

The new process still makes use of a transition metal catalyst, a dirhodium complex, that effectively catalyzes the direct introduction of unprotected alkylamino groups into aromatic rings.

While there are many established methods to prepare free aromatic amines for use in drugs and other bioactive materials, none of them are simple, Kürti said. The most efficient processes to date require a minimum of three steps.

“When you do things in multiple steps, you lose material with each step,” he said. “With our process, you gain not only speed but also efficiency and high material throughput, because you’re going to have the desired compound in just one step.”

“Anything you can do that expedites the introduction of nitrogen in these molecules and reduces the cost of production is going to be beneficial for drug development and for reducing the cost of drugs,” said Falck, the Robert A. Welch Distinguished Chair in Chemistry at UTSWMC. “Up to now, chemists have had to rely on circuitous routes to be able to introduce these nitrogens. And we’ve achieved access directly in a much more efficient process than the alternatives.”

“Anybody who is interested in streamlining the synthesis of complex compounds that contain nitrogen, now has a one-step, one-flask process,” Kürti added. “Agrochemical companies, drug-discovery companies and anybody who makes fine chemicals will find this a very interesting tool.”


Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50